Oyster Therapeutics Series A

Oyster Therapeutics is a London-based pharmaceutical company developing next-generation targeted protein degraders with an initial focus on tau-driven neurodegenerative diseases such as Alzheimer's. Its proprietary SELFTAC platform transforms large bifunctional degraders into small molecules via a reversible linker to enable oral bioavailability and CNS penetration. Its lead program is a small-molecule oral degrader designed to selectively clear pathological tau while preserving healthy tau, advanced in collaboration with Massachusetts General Hospital.